Calling All High-Risk Multiple Myeloma Patients: Support Options for You!

If you're living with high-risk myeloma, you don't have to navigate this journey on your own. We've created a supportive community just for you. Our virtual support group will kick off on October 17, 2023, at 4:00 p.m. PST | 7:00 p.m. EST. Join us for an informative session featuring IMF Chief Medical Officer Dr. Joseph Mikhael, who will delve into the criteria used to identify high-risk myeloma cases. If you're interested in participating and would like more information, contact us at [email protected]. For a comprehensive overview, visit HRMM.support.myeloma.org. Remember, you're not alone—our community is here for you!

Las Voces de Mieloma Support Group (Spanish-Virtual)

Join Las Voces de Mieloma Support Group (Spanish/Virtual), on Tuesday, October 17, 10:00 a.m.–11:00 a.m. (Pacific)

Guest speaker:  Jesus G. Berdeja, MD
Director, Multiple Myeloma Research, Tennessee Oncology — Nashville, Tennessee

Jesus G. Berdeja received his undergraduate degree from Stanford University and medical degree from Harvard University. He completed his internship and residency in the Department of Internal Medicine at the University of California in San Francisco and fellowships in medical oncology and hematology at Johns Hopkins University School of Medicine in Baltimore. Prior to joining the staff at Tennessee Oncology and the Sarah Cannon Research Institute, Dr. Berdeja held appointments in the Stem Cell and Bone Marrow Transplant Program and the Division of Hematology and Oncology at Loma Linda University in Loma Linda, California.

Dr. Berdeja specializes in clinical hematology, with a focus on multiple myeloma and has been certified a Diplomate in hematology by the American Board of Internal Medicine. He is a frequent peer reviewer for many prominent medical journals. Additionally, he is an active member of several professional organizations, including the International Myeloma Society, the American Society of Clinical Oncology, the American Society of Hematology, the International Myeloma Working Group and the Clinical Trials Myeloma Intergroup Committee.

An active researcher, Dr. Berdeja has been the principal investigator of many funded clinical trials in the field of multiple myeloma. He has published extensively in the peer-reviewed literature and is a frequent invited lecturer.

For any questions, please email [email protected].

Las Voces de Mieloma Grupo de Apoyo (Virtual/Español)

Las Voces de Mieloma Grupo de Apoyo (en Español/Virtual), Martes, 17 de Octubr, 10:00 a.m.-11:00 a.m. (Tiempo Pacífico).

Invitado Especial: Jesus G. Berdeja, MD

Director, Investigación del Mieloma Múltiple, Tennessee Oncology — Nashville, Tennessee

Jesús G. Berdeja recibió su licenciatura de la Universidad de Stanford y su título de médico de la Universidad de Harvard. Completó su internado y residencia en el Departamento de Medicina Interna de la Universidad de California en San Francisco y becas en oncología médica y hematología en la Facultad de Medicina de la Universidad Johns Hopkins en Baltimore. Antes de unirse al personal de Tennessee Oncology y de Sarah Cannon Research Institute, el Dr. Berdeja ocupó cargos en el Programa de Trasplante de Células Madre y Médula Ósea y en la División de Hematología y Oncología de la Universidad de Loma Linda en Loma Linda, California.  

El Dr. Berdeja se especializa en hematología clínica, con un enfoque en el mieloma múltiple y ha sido certificado como Diplomado en hematología por la Junta Americana de Medicina Interna. Es un revisor frecuente de muchas revistas médicas prominentes. Además, es miembro activo de varias organizaciones profesionales, incluyendo la Sociedad Internacional de Mieloma, la Sociedad Americana de Oncología Clínica, la Sociedad Americana de Hematología, el Grupo de Trabajo Internacional de Mieloma y el Comité Intergrupal de Mieloma de Ensayos Clínicos.

Un investigador activo, el Dr. Berdeja ha sido el investigador principal de muchos ensayos clínicos financiados en el campo del mieloma múltiple. Ha publicado extensamente en la literatura revisada por pares y es un ponente invitado frecuente.

 Para preguntas, envíe un correo electrónoco a: [email protected].

Lace Up Your Sneakers for the 11th Annual Miracles for Myeloma 5K Run/Walk

Lace up your sneakers and join us for an incredible cause at the 11th Annual Miracles for Myeloma 5K Run/Walk. We're thrilled to invite you to a day filled with hope, inspiration, and community as we gather on October 14 in Oak Ridge Park in Clark, New Jersey. You can join us at 10:00 a.m. EST on that day to race in person, or you can log your miles and race virtually. Whether you're a seasoned runner or just love a leisurely stroll, this event is for everyone. By participating, you're making a direct impact on the lives of those affected by myeloma and contributing to groundbreaking research that brings us closer to a cure. Contact Ron Pask at 732-574-9182 or [email protected] to learn more. See you at the starting line!

Medicare Open Enrollment Period Begins October 15

Medicare's Open Enrollment Period is October 15 - December 7. This timeframe is your chance to explore Medicare Plans and see what works for you. Plans can change from year to year, and your health needs may change, too. The International Myeloma Foundation and our InfoLine team do not have recommendations about Medicare. We do, however, encourage you to explore Medicare.gov, or contact your local State Health Insurance Assistance Program (SHIP) to get the phone number for Medicare assistance for your state. 

Learn About Autologous Stem Cell Transplant Through the Myeloma University Video Series

Developed by the IMF’s Nurse Leadership Board, Myeloma University is a FREE online educational program designed for nurses and other healthcare professionals to gain knowledge about multiple myeloma. Just released in this series is the module on Autologous Stem Cell Transplant (ASCT) for Treatment of Multiple Myeloma. Tune in to gain an understanding of the ASCT process, to review concepts of who should undergo an ASCT, and to Identify special nursing considerations for the community-based provider. 

#ASKDRDURIE | Dr. Durie's Weekly Web Video Series

What is the SpineJack, and how can it benefit myeloma patients?